Evidence map›Paper›PMID 35583697›Full record

ArticleCancer causes & control : CCC2022

The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.

Cody Ramin, Gretchen L Gierach, Mustapha Abubakar, Lene H S Veiga, Jacqueline B Vo, Rochelle E Curtis, Erin J Aiello Bowles, Heather Spencer Feigelson, Diana S M Buist, Amy Berrington de Gonzalez and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Cody RaminDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Gretchen L GierachDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Mustapha AbubakarDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Lene H S VeigaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Jacqueline B VoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Rochelle E CurtisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
Heather Spencer FeigelsonBernard J. Tyson Kaiser Permanente School of Medicine, Pasadena, CA, USA.
Diana S M BuistKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.
Amy Berrington de GonzalezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA.
Clara BodelonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive, Bethesda, MD, USA. clara.bodelon@nih.gov.ORCID http://orcid.org/0000-0002-6578-2678

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Anna N. A. Tosteson · 2011 to 2026
$52.9M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
Intramural NIH HHS Z99 CA999999NCI NIH HHS N01 CN067009NCI NIH HHS N01 PC035142NCI NIH HHS P01 CA154292NCI NIH HHS R50 CA211115
6 · The paper itself

Abstract

purposeEstrogen receptor (ER) + /progesterone receptor (PR) - or ER-/PR + breast cancer prognosis has not been well-described outside of clinical trials. We evaluated the relationship between ER/PR (ER + /PR-, ER-/PR + , ER + /PR + , ER-/PR-) subgroups and breast cancer-specific mortality within a general community setting in the US.

methodsA Retrospective cohort of 11,737 women diagnosed with breast cancer between 1990 and 2016 within US integrated healthcare systems (median follow-up = 7 years; 1,104 breast cancer-specific deaths) were included in this analysis. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) adjusting for site, demographic and clinicopathological characteristics, and treatment (surgery/radiotherapy, chemotherapy, endocrine therapy).

resultsBreast cancer-specific mortality was higher for those with ER + /PR- (n = 1,233) compared with ER + /PR + tumors (n = 8,439) before (HR = 1.43; 95% CI = 1.17-1.75) and after treatment adjustment (HR = 1.58; 95% CI = 1.27-1.97). ER + /PR- breast cancer-specific mortality remained higher than ER + /PR + tumors when stratified by treatment received. Breast cancer-specific mortality was similar in ER-/PR + (n = 161) compared with ER + /PR + tumors.

conclusionOur findings suggest that ER + /PR- tumors may have worse breast cancer-specific mortality than ER + /PR + tumors in a community setting.

Indexed as

Breast NeoplasmsDelivery of Health Care, IntegratedErb-b2 Receptor Tyrosine KinasesFemaleHormonesHumansPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesErb-b2 Receptor Tyrosine KinasesHormonesReceptors, EstrogenReceptors, ProgesteroneBreast neoplasmChemotherapyEstrogen receptorMortalityProgestogen receptorRadiotherapyTamoxifen aromatase inhibitors

Identifiers

PMID35583697
PMCPMC9701354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.